Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Dose Escalation and Expansion Study of TH1902 in Patients With Advanced Solid Tumors

NCT04706962 is registered in ClinicalTrials.gov with Theratechnologies as lead sponsor.

NCT NCT04706962
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04706962 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Dose Escalation and Expansion Study of TH1902 in Patients With Advanced Solid Tumors
Lead sponsor
Theratechnologies
Phase
Phase 1
Overall status
Active, not recruiting
Start date
March 4, 2021
Completion date
January 31, 2026
Enrollment
70 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous melanoma, endometrial cancer, epithelial ovarian cancer, hormone receptor-positive breast cancer, prostate cancer, small-cell lung cancer, solid tumor, sort1+ cancers, thyroid cancer, tnbc - triple-negative breast cancer